Medical cannabidiol – is there anything it can't do?
Cannabidiol as potential anticancer drug
Article first published online: 10 JAN 2013
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society
British Journal of Clinical Pharmacology
Volume 75, Issue 2, pages 303–312, February 2013
How to Cite
Massi, P., Solinas, M., Cinquina, V. and Parolaro, D. (2013), Cannabidiol as potential anticancer drug. British Journal of Clinical Pharmacology, 75: 303–312. doi: 10.1111/j.1365-2125.2012.04298.x
- Issue published online: 10 JAN 2013
- Article first published online: 10 JAN 2013
- Accepted manuscript online: 17 APR 2012 03:58AM EST
- Received; 30 January 2012; Accepted; 10 April 2012; Accepted Article Published Online; 17 April 2012
- cancer cells;
Over the past years, several lines of evidence support an antitumourigenic effect of cannabinoids including Δ9-tetrahydrocannabinol (Δ9-THC), synthetic agonists, endocannabinoids and endocannabinoid transport or degradation inhibitors. Indeed, cannabinoids possess anti-proliferative and pro-apoptotic effects and they are known to interfere with tumour neovascularization, cancer cell migration, adhesion, invasion and metastasization. However, the clinical use of Δ9-THC and additional cannabinoid agonists is often limited by their unwanted psychoactive side effects, and for this reason interest in non-psychoactive cannabinoid compounds with structural affinity for Δ9-THC, such as cannabidiol (CBD), has substantially increased in recent years. The present review will focus on the efficacy of CBD in the modulation of different steps of tumourigenesis in several types of cancer and highlights the importance of exploring CBD/CBD analogues as alternative therapeutic agents.